Milatuzumab Plus Veltuzumab Demonstrate Activity in B-Cell Non-Hodgkin Lymphoma

Share this content:
Combination veltuzumab and milatuzumab demonstrated activity in heavily pre-treated relapsed or refractory indolent non-Hodgkin lymphoma.
Combination veltuzumab and milatuzumab demonstrated activity in heavily pre-treated relapsed or refractory indolent non-Hodgkin lymphoma.

Combination therapy with veltuzumab and milatuzumab demonstrated activity in a population of heavily pre-treated patients with relapsed or refractory indolent non-Hodgkin lymphoma, a recent study published in the British Journal of Haematology has shown.

For the phase I/II study, researchers sought to assess the activity and safety of veltuzumab, a humanized anti-CD20 antibody, and milatuzumab, a humanized anti-CD74 antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma after the combination showed anti-tumor activity in vitro and in vivo.

Researchers enrolled 35 patients. All patients received an induction of veltuzumab 200mg/m2 weekly in combination with escalating doses of milatuzumab at 8, 16, and 20mg/kg weekly for 4 weeks.

Patients whose disease did not progress could receive an extended induction with treatment on weeks 12, 20, 28, and 26.

RELATED: Bendamustine Plus Rituximab May Be Safe, Effective for Lymphoma

Results showed that 29% of patients complete all 36 weeks of treatment. Researchers observed an overall response rate of 24% and a median duration of response of 12 months.

Responses were observed at all dose levels. Of the 63% of patients who were rituximab refractory, 50% achieved responses.

In regard to safety, immunotherapy-associated grade 3-4 adverse events included anemia, atrial tachycardia, fatigue, hyperglycemia, infusion reactions, leukopenia, lymphopenia, and neutropenia.

Reference

  1. Christian BA, Poi M, Jones JA, et al. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Brit J Haematol. 2015. [Epub ahead of print]. doi: 10.1111/bjh.13354.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters